Corroborating a functional role of GIPR, GLP-1GIPLani decreased body weight and food intake with increased efficacy compared with GLP-1Lani, but with equal efficacy to co-therapy of GLP-1Lani and a long-acting GIPR agonist (acyl-GIP) (Fig
It is also not a breakthrough weight-loss solution, and the research does not support calling it one
In the CRPC, choline, amino acid, and glycolytic metabolism are promoted more than OXPHOS [92]
Nevertheless, even the most effective marketed incretin, the GLP-1/GIP dual agonist tirzepatide, produces a maximum HbA1c reduction of ~2.6%, with fewer than half of participants in the SURPASS trials reaching normoglycemia (HbA1c 10%), vehicle-treated animals lost ~40% of body weight over 3 months, consistent with prior reports showing comparable reductions from ~40 g at week 10 to ~25 g by week 20 19